MTOR and nonpapillary renal cell carcinoma: However, sunitinib treatment in metastatic PRCC induced a slightly better PFS compared to the mTOR inhibitor everolimus and this gives support to the choice of the guidelines from the National Comprehensive Cancer Network and the European Society for Medical Oncology both recommending sunitinib as first line therapy in metastatic non-CCRCC.